Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C546S201000, C546S277400
Reexamination Certificate
active
10835998
ABSTRACT:
3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.
REFERENCES:
patent: 5693655 (1997-12-01), Bottcher et al.
patent: 0 666 258 (1995-08-01), None
patent: WO 99/67237 (1999-12-01), None
patent: WO 00/34263 (2000-06-01), None
patent: WO 00/43382 (2000-07-01), None
Arborelius, L. et al., “5-HT1Areceptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram,”Naunyn-Schmiedeberg's Arch. Pharmacol.1995, 352: 157-165.
Invernizzi, R. et al., “Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1Areceptors,”Eur. J. Pharmacol.1994, 260: 243-246.
Artigas, F. et al., “Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1Aantagonists,”Trends Neurosci.1996, 19(9): 378-383.
Jean-Luc Malleron et al., “New Indole Derivatives as Potent and Selective Serotonin Uptake Inhibitors,”J. Med. Chem.1993, 36: 1194-1202 [plus erratum: p. 2242].
Wustrow et al., “3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as Dopamine D2 Partial Agonists and Autoreceptor Agonists,”J. Med. Chem.1997, 40: 250-259.
Perez, V., et al., “Randomised double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment,”The Lancet, 1997, 349: 1594-1597.
Feiger, A., “A Double-Blind Comparison of Gepirone Extended Release, Imipramine, and Placebo in the Treatment of Outpatient Major Depression,”Psychopharmacol. Bull., 1996, 32(4): 659-665.
Wilcox, C. et al., “A Double-Blind Trial of Low- and High-Dose Ranges of Gepirone-ER Compared With Placebo in the Treatment of Depressed Outpatients,”Psychopharmacol. Bull., 1996, 32(3): 335-342.
Grof, P. et al., “An open study of oral flesinoxan, a 5-HT1Areceptor agonist, in treatment-resistant depression,”International Clinical Psychopharmacology, 1993, 8: 167-172.
Dimitriou, E. et al., “Buspirone Augmentation of Antidepressant Therapy,”J. Clinical Psychopharmacol., 1998, 18(6): 465-469.
Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, Pa (1985).
Bundgaard (ed.), Design of Prodrugs, Elsevier (1985).
Higuchi and Stella (eds.), Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975).
Krogsgaard-Larsen, et al., (ed.), Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991).
Bundgaard, H. et al., “Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Delivery Reviews, Elsevier Science Publishers, 8:1-38 (1992).
Bundgaard, J. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”Pharmaceutical Sciences, 77(4):285-298 (Apr. 1988).
Cheetham, S. C. et al., “[3H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates With [3H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments,”Neuropharmacol., 1993, 32: 737-743.
Cheng, Y-C. et al., “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol., 1973, 22: 3099-3108.
Hall, M. D. et al. “[3H]8-Hydroxy-2-(Di-n-Propylamino)Tetralin Binding to Pre- and Postsynaptic 5-Hydroxytryptamine Sites in Various Regions of the Rat Brain,”J. Neurochem., 1985, 44(6): 1685-1696.
Lazareno, S. and Birdsall, N.J.M., “Pharmacological characterization of acetylcholine-stimulated [35S]-GTPγS binding mediated by human muscarinic m1—m4 receptors: antagonist studies,”Br. J. Pharmacol., 1993, 109:1120-1127.
Dos Santos Osvaldo
Gu Yansong
Venkatesan Aranapakam Mudumbai
Morris Patricia L.
Wyeth
LandOfFree
Piperidinyl indole and tetrohydropyridinyl indole... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidinyl indole and tetrohydropyridinyl indole..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinyl indole and tetrohydropyridinyl indole... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873233